Cost effectiveness analysis of rheumatoid arthritis outpatient at a hospital in bandung
DOI:
https://doi.org/10.35335/midwifery.v10i6.1155Keywords:
DAS-28, Cost effectiveness analysis, Rheumatoid arthritisAbstract
Rheumatoid arthritis is a chronic systemic autoimmune disease of the joints with unknown etiology. treatment therapy is carried out to reduce the symptoms of inflammation, one of which is by using methylprednisolone and methotrexate. treatment is carried out in the long term. this study aims to analyze the cost-effectiveness of combined methylprednisolone in rheumatoid arthritis patients. the study used a retrospective descriptive analytic design. the data were taken from 31 outpatient medical records in hasan sadikin hospital from january 2017-december 2018. the research data included the das28 score, doctor visit fees, medical expenses, and laboratory fees. cost-effectiveness analysis is done by calculating the average cost effectiveness ratio (acer) and incremental cost effectiveness ratio (icer). the results showed 17 patients using methylprednisolone+methotrexate, 6 patients using methylprednisolone+sulfasalazine, 1 patient using methylprednisolone+cyclosporine, 2 patients using methylprednisolone+methotrexate+chloroquine, 3 patients using methylprednisolone+chloroquine+cyclosporine and 2 patients using methylprednisolone+chloroquine. the lowest acer value was obtainedwhen the combination of methylpredisolone+chloroquine was rp. 453,716 per effectiveness with an icer value of rp. 11,686 per effectiveness. this study concludes that the combination of methylprednisolone + chloroquine is the most effective therapy compared to other combinations of methylprednisolone.
Downloads
References
Achmad, A., Suryana, B. P., & Rahmayanti, T. Y. (2020). Efektifitas Kepatuhan Terapi Metotreksat melalui Disease Activity Score 28 (DAS28) pada Pasien Artritis Reumatoid. Pharmaceutical Journal of Indonesia, 2020(2), 103–107.
Aletaha, D., & Smolen, J. S. (2018). Diagnosis and Management of Rheumatoid Arthritis: A Review. JAMA - Journal of the American Medical Association, 320(13), 1360–1372. https://doi.org/10.1001/jama.2018.13103
Badan Penelitian dan Pengembangan Kesehatan. (2019). Laporan Nasional Riset Kesehatan Dasar 2018 (pp. 152–162). Lembaga Penerbit Badan Penelitian dan Pengembangan Kesehatan.
Benucci, M., Saviola, G., Manfredi, M., Sarzi-Puttini, P., & Atzeni, F. (2011). Cost effectiveness analysis of disease-modifying antirheumatic drugs in rheumatoid arthritis. A systematic review literature. International Journal of Rheumatology, 2011. https://doi.org/10.1155/2011/845496
Chatterjee, S., Levin, C., & Laxminarayan, R. (2013). Unit Cost of Medical Services at Different Hospitals in India. PLoS ONE, 8(7). https://doi.org/10.1371/journal.pone.0069728
Citraningtyas, G., Ruru, R. I., & Nalang, A. (2018). Analisis Efektifitas Biaya Penggunaan Antibiotik Sefiksim dan Sefotaksim Pasien Diare di Rumah Sakit X Tahun 2017. Jurnal Manajemen Dan Pelayanan Farmasi, 8(4), 145–152.
Dissanayake, K., Jayasinghe, C., Wanigasekara, P., Dissanayake, J., & Sominanda, A. (2022). Validity of clinical disease activity index (CDAI) to evaluate the disease activity of rheumatoid arthritis patients in Sri Lanka: A prospective follow up study based on newly diagnosed patients. PLoS ONE, 17(11 November), 1–11. https://doi.org/10.1371/journal.pone.0278285
Dunlop, W., Iqbal, I., Khan, I., Ouwens, M., & Heron, L. (2013). Cost-effectiveness of modified-release prednisone in the treatment of moderate to severe rheumatoid arthritis with morning stiffness based on directly elicited public preference values. ClinicoEconomics and Outcomes Research, 5(1), 555–564. https://doi.org/10.2147/CEOR.S47867
Faridah, I. N., Syahfitri, T. L., Nugroho, R. A., Supadmi, W., Dania, H., & Perwitasari, D. A. (2022). Direct Medical Cost Analysis of Dengue Patients: A Retrospective Study. Jurnal Farmasi Dan Ilmu Kefarmasian Indonesia, 9(2), 177–184. https://doi.org/10.20473/jfiki.v9i22022.177-184
Gestel, A. M. V. A. N., Laan, R. F. J. M., Haagsma, C. J., Putte, L. B. A. V. A. N. D. E., & Riel, P. L. C. M. V. A. N. (1995). Oral Steroids As Bridge Therapy In Rheumatoid Arthritis Patients Starting With Parenteral Gold . A Randomized Double-Blind Placebo-Controlled Trial. British Journal of Rheumatology, 34, 347–351.
Gholami, A., Azizpoor, J., Aflaki, E., Rezaee, M., & Keshavarz, K. (2021). Cost-Effectiveness Analysis of Biopharmaceuticals for Treating Rheumatoid Arthritis: Infliximab, Adalimumab, and Etanercept. BioMed Research International, 2021. https://doi.org/10.1155/2021/4450162
Goma, E. I., Sandy, A. T., & Zakaria, M. (2021). Analisis Distribusi dan Interpretasi Data Penduduk Usia Produktif Indonesia Tahun 2020. Jurnal Georafflesia, 6(1), 20–27.
Haridoss, M., Bagepally, B. S., & Natarajan, M. (2021). Health-related quality of life in rheumatoid arthritis: Systematic review and meta-analysis of EuroQoL (EQ-5D) utility scores from Asia. International Journal of Rheumatic Diseases, 24(3), 314–326. https://doi.org/10.1111/1756-185X.14066
Hartman, L., El Alili, M., Cutolo, M., Opris, D., Da Silva, J. A. P., Szekanecz, Z., Buttgereit, F., Masaryk, P., Bos, R., Kok, M. R., Paolino, S., Coupé, V. M. H., Lems, W. F., & Boers, M. (2022). Cost-effectiveness and cost-utility of add-on, low-dose prednisolone in patients with rheumatoid arthritis aged 65+: The pragmatic, multicenter, placebo-controlled GLORIA trial. Seminars in Arthritis and Rheumatism, 57(October). https://doi.org/10.1016/j.semarthrit.2022.152109
Hejrati, A., Taghadosi, M., Alizadeh-Navaei, R., Hosseinzadeh, S., Bashash, D., Esmaili, M., & Zafari, P. (2020). Neopterin serum level does not reflect the disease activity in rheumatoid arthritis: A systematic review and meta-analysis. IUBMB Life, 72(12), 2563–2571. https://doi.org/10.1002/iub.2398
Hidayat, R., Suryana, B. P. P., Wijaya, L. K., Ariane, A., Hellmi, R. Y., Adnan, E., & Sumariyono. (2021). Diagnosis dan Pengelolaan Artritis Reumatoid (Rheumatoid Arthritis Diagnosis and Management). In Perhimpunan Reumatologi Indonesia.
Iwami, R. S., Moura, M. D. G., Sorrilha, F. B., & Bergamaschi, C. de C. (2022). Effectiveness and safety of oral corticosteroids in the treatment of rheumatoid arthritis : a systematic review. Brazilian Journal of Hospital Pharmacy and Health Services, 13(1), 1–10. https://doi.org/10.30968/rbfhss.2022.131.0749.RBFHSS
Karaeng, N. D., Makhmud, A. I., & Liaury, K. (2021). The use of risperidone-combination and haloperidol-combination in schizophrenia patients: A cost utility analysis in psychiatric hospital of Prof. V.L. Ratumbuysang. Medicina Clinica Practica, 4, 100236. https://doi.org/10.1016/j.mcpsp.2021.100236
Ma, M. H. Y., Ma, M. H. Y., Ma, M. H. Y., Defranoux, N., Defranoux, N., Li, W., Li, W., Sasso, E. H., Ibrahim, F., Scott, D. L., Cope, A. P., & Cope, A. P. (2020). A multi-biomarker disease activity score can predict sustained remission in rheumatoid arthritis. Arthritis Research and Therapy, 22(1), 1–12. https://doi.org/10.1186/s13075-020-02240-w
Mahony, J. F. O. (2020). Does Cost ‑ Effectiveness Analysis Really Need to Abandon the Incremental Cost ‑ Effectiveness Ratio to Embrace Net Benefit ? PharmacoEconomics, 0123456789, 2–4. https://doi.org/10.1007/s40273-020-00931-5
Radu, A.-F., & Bungau, S. G. (2021). Management of Rheumatoid Arthritis: An Overview. Cells, 10(2857), 1–33. https://doi.org/10.1016/j.mpmed.2014.02.004
Romo-garcÃÂÂa, M. F., Zapata-zuñiga, M., & Castañeda-delgado, J. E. (2020). The Role of Estrogens in Rheumatoid Arthritis Physiopathology. In R. H. A. Mohammed (Ed.), Rheumatoid Arthritis - Other Perspectives towards a Better Practice. IntechOpen.
Savitri, S. A., Kartidjo, P., Rahmadi, A. R., & Vikasari, S. N. (2019). Hubungan Pemilihan Obat dan Keberhasilan Terapi Pasien Rheumatoid Arthritis. Jurnal Farmasi Klinik Indonesia, 8(4), 237–245. https://doi.org/10.15416/ijcp.2019.8.4.237
Tonin, F. S., Aznar-Lou, I., Pontinha, V. M., Pontarolo, R., & Fernandez-Llimos, F. (2021). Principles of pharmacoeconomic analysis: The case of pharmacist-led interventions. Pharmacy Practice, 19(1), 1–10. https://doi.org/10.18549/PharmPract.2021.1.2302
Xu, Y., & Wu, Q. (2021). Prevalence Trend and Disparities in Rheumatoid Arthritis among US Adults , 2005 – 2018. Journal of Clinical Medicine, 10(3289), 2–13.
